CIAPIN1 and ABCA13 are markers of poor survival in metastatic ovarian serous carcinoma

Abstract

Background: The objective of this study was to investigate the expression and clinical role of 14 genes previouslyshown to be associated with chemotherapy response and/or progression-free survival in a smaller series of ovarianserous carcinoma effusions.Methods: Advanced-stage serous ovarian carcinoma effusions (n = 150) were analyzed for mRNA expression ofAKR1C1, ABCA4, ABCA13, ABCB10, BIRC6, CASP9, CIAPIN1, FAS, MGMT, MUTYH, POLH, SRC, TBRKB and XPA usingquantitative real-time PCR. mRNA expression was studied for association with clinicopathologic parameters, includingchemotherapy response and survival.Results: ABCA4 mRNA expression was significantly related to better (complete) chemotherapy response at diagnosis inthe entire cohort (p = 0.018), whereas higher POLH mRNA levels were significantly related to better chemoresponse atdiagnosis in analysis to 58 patients with pre-chemotherapy effusions treated with standard chemotherapy (carboplatin +paclitaxel; p = 0.023). In univariate survival analysis for patients with pre-chemotherapy effusions (n = 77), CIAPIN1 mRNAexpression was significantly related to shorter overall (p = 0.007) and progression-free (p = 0.038) survival, whereasABCA13 mRNA expression was significantly related to shorter OS (p = 0.024). Higher CIAPIN1 mRNA expression wasan independent marker of poor overall survival in Cox multivariate analysis (p = 0.044).Conclusions: Our data identify ABCA4 and POLH as markers of better chemotherapy response in metastaticserous carcinoma. CIAPIN1 and ABCA13 may be novel markers of poor outcome in pre-chemotherapy serouscarcinoma effusions.